Date: 2013-02-25
Type of information:
phase: 1
Announcement: initiation
Company: Okairos (Italy)
Product: vaccine against respiratory syncytial virus
Action mechanism:
Disease: respiratory syncytial virus (RSV) infections
Therapeutic area: Infectious diseases
Country: UK
Trial details:
Latest
news: Okairos has announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in infants and children. This clinical trial will enroll 40 healthy adult volunteers in the UK, with endpoints measuring the vaccine’s safety and immunogenicity.
Okairos has evaluated its RSV vaccine candidate in well-established preclinical models and found that it stimulates both a strong neutralizing antibody and a robust T-cell response. Okairos’ vaccine candidate has also been shown to provide complete protection against RSV infection in challenge experiments in both cotton rats and neonatal calves, as well as an excellent safety profile, both before and after challenge.
